UBS Reiterates Buy Rating on Oruka Therapeutics (ORKA) Following Data Readout

April 6, 2026 9:27 AM

UBS analyst Michael Yee reiterated a Buy rating and $50.00 price target on Oruka Therapeutics (NASDAQ: ORKA).The analyst commented, "ORKA ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found